Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TYMP | P19971 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CDC7 | O00311 | 1/20 | 0.33 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | CNOT7 | Q9UIV1 | 1/20 | 0.31 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.31 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18816387 | 0.81 | ALDH1A1 (0.34) | GDAALDH1A1KDM4EHPGDMAPK1 | |
| SCHEMBL20023764 | 0.72 | GDA (0.34) | GDAALDH1A1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL23692399 | 0.70 | KDM4C (0.32) | ALDH1A1KDM4EHPGDSMN1; SMN2GSK3B | |
| SCHEMBL24547690 | 0.69 | ALDH1A1 (0.47) | GDAALDH1A1PARP1HPGDSMN1; SMN2 | |
| SCHEMBL2193951 | 0.69 | ALDH1A1 (0.43) | GDAALDH1A1TYMPKDM4ECA12 | |
| SCHEMBL18255880 | 0.68 | MAPK1 (0.46) | ALDH1A1KDM4EHPGDMAPK1CYP3A4 | |
| SCHEMBL30577475 | 0.67 | PARP1 (0.50) | ALDH1A1KDM4ECA12PARP1CA9 | |
| SCHEMBL18362241 | 0.67 | PARP1 (0.43) | ALDH1A1KDM4EPARP1HPGDSMN1; SMN2 | |
| SCHEMBL6792539 | 0.66 | GRIN2D (0.36) | ALDH1A1KDM4EPARP1HPGDKDM4C | |
| SCHEMBL22119141 | 0.66 | ALDH1A1 (0.36) | ALDH1A1KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153365-B2 | Oligonucleotide analogues | EXIQON A/S (DK) | 2012-04-10 | — | — | US | claimed |
| US-8034909-B2 | Oligonucleotide analogues | EXIQON A/S (DK) | 2011-10-11 | — | — | US | claimed |
| US-20110245327-A1 | Oligonucleotide Analogues | EXIQON A/S (DK) | 2011-10-06 | — | — | US | claimed |
| US-20100279895-A1 | OLIGONUCLEOTIDE ANALOGUES | EXIQON A/S (DK) | 2010-11-04 | — | — | US | claimed |
| US-7374882-B2 | Method for base sequencing and biologically active nucleic acids | RIKEN (JP) | 2008-05-20 | — | — | US | claimed |
| US-7034133-B2 | Locked Nucleoside Analogues is a biochemical conjugate of nucleotides; as an aptamer in specific binding of antibiotics, drugs, amino acids, peptides, enzymes, saccharides, polysaccharides; heat resistance | EXIQON A/S (DK) | 2006-04-25 | — | — | US | claimed |
| US-6794499-B2 | BICYCLIC LOCKED NUCLEOSIDE ANALOGUES | EXIQON A/S (DK) | 2004-09-21 | — | — | US | claimed |
| US-20040115665-A1 | Method for base sequencing and biologically active nucleic acids | RIKEN (JP) | 2004-06-17 | — | — | US | claimed |
| US-6670461-B1 | Bi-, tri, or polycyclic nucleoside analogues having a \"locked\" structure capable of forming heat resistant nucleobase specific duplexes and triplexes with single and double stranded nucleic acids. | EXIQON A/S (DK) | 2003-12-30 | — | — | US | claimed |
| US-6037120-A | PREPARATION OF A COMPLEMENTARY OLIGONUCLEOTIDE AND HYBRIDIZING TO DNA OR RNA IN SOLUTION | BENNER, STEVEN | 2000-03-14 | — | — | US | claimed |
| US-5965364-A | Method for selecting functional deoxyribonucleotide derivatives | BENNER, STEVEN | 1999-10-12 | — | — | US | claimed |
| US-5432272-A | Genetic engineering | BENNER, STEVEN | 1995-07-11 | — | — | US | claimed |
| US-12534470-B2 | DNA polymerase IIIC inhibitors and use thereof | Acurx Pharmaceuticals, Inc. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20230250102-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | Acurx Pharmaceuticals, Inc. | 2023-08-10 | — | — | US | disclosed |
| US-20230250102-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | Acurx Pharmaceuticals, Inc. | 2023-08-10 | — | — | US | disclosed |
| US-20230250102-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | Acurx Pharmaceuticals, Inc. | 2023-08-10 | — | — | US | disclosed |
| EP-1970373-A1 | ALICYCLIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-09-17 | — | — | EP | disclosed |
| EP-1956009-A1 | AROMATIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-7374882-B2 | Method for base sequencing and biologically active nucleic acids | RIKEN (JP) | 2008-05-20 | — | — | US | disclosed |
| US-20040115665-A1 | Method for base sequencing and biologically active nucleic acids | RIKEN (JP) | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12534470-B2 | DNA polymerase IIIC inhibitors and use thereof | POLR1A, POLR2H, POLN | GDA 2263/4885ALDH1A1 2357/4885TYMP 94/4885 |
| US-20110245327-A1 | Oligonucleotide Analogues | POLRMT, POLM, POLN | GDA 125/4885ALDH1A1 3811/4885TYMP 19/4885 |
| US-20230250102-A1 | DNA Polymerase IIIC Inhibitors and Use Thereof | POLI, POLN, POLB | GDA 200/4885ALDH1A1 3028/4885TYMP 28/4885 |
| US-20100279895-A1 | OLIGONUCLEOTIDE ANALOGUES | POLRMT, POLM, POLN | GDA 125/4885ALDH1A1 3811/4885TYMP 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.